Edgestream Partners’s Sarepta Therapeutics SRPT Stock Holding History

Edgestream Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-108,725	Closed	-$2.34M	–	1097
2025 Q4	$2.34M	Sell	108,725 -62,072	-36%	-$1.31M	0.07%	492
2025 Q3	$3.29M	Buy	170,797 +87,818	+106%	+$1.57M	0.1%	389
2025 Q2	$1.42M	Buy	82,979 +74,427	+870%	+$3.18M	0.04%	589
2025 Q1	$546K	Buy	+8,552	New	+$900K	0.02%	687
2024 Q4	–	Sell	-18,459	Closed	-$2.31M	–	1075
2024 Q3	$2.31M	Buy	+18,459	New	+$2.55M	0.1%	360
2024 Q2	–	Sell	-4,841	Closed	-$627K	–	1025
2024 Q1	$627K	Buy	+4,841	New	+$593K	0.03%	603
2023 Q4	–	Sell	-3,648	Closed	-$442K	–	1053
2023 Q3	$442K	Buy	3,648 +905	+33%	+$102K	0.04%	619
2023 Q2	$314K	Buy	+2,743	New	+$354K	0.03%	623

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Edgestream Partners's SRPT Position: Q1 2026 in Review

Edgestream Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 108,725 shares — an estimated $2.34M sold.

Edgestream Partners first reported a position in SRPT in Q2 2023 and held it in 8 quarters. The position peaked at $3.29M in Q3 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Edgestream Partners reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
Edgestream Partners sold 108,725 Sarepta Therapeutics shares in Q1 2026, an estimated $2.34M.
Edgestream Partners first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 8 quarters.
Edgestream Partners's Sarepta Therapeutics position peaked at $3.29M in Q3 2025.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.